Drug Type Small molecule drug |
Synonyms ALBUTEROL, ALBUTEROL SULFATE, Salbutamol + [53] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Jan 1973), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Salbutamol sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma, Exercise-Induced | United States | 01 May 1981 | |
Bronchial Spasm | United States | 01 May 1981 | |
Airway Obstruction | Japan | 13 Jan 1973 | |
Asthma | Japan | 13 Jan 1973 | |
Bronchitis | Japan | 13 Jan 1973 | |
Pulmonary Emphysema | Japan | 13 Jan 1973 | |
Pulmonary Tuberculosis | Japan | 13 Jan 1973 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | NDA/BLA | Canada | - | |
Persistent asthma | Phase 3 | United States | 01 Oct 2010 | |
Childhood asthma | Phase 3 | United States | 10 Jun 2006 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 01 Sep 2004 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | Puerto Rico | 01 Sep 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United Kingdom | 01 Apr 2012 | |
airway disease | Phase 1 | - | 01 Mar 2009 | |
Mild asthma | Clinical | India | 15 Aug 2022 | |
Mild asthma | Clinical | Taiwan Province | 15 Aug 2022 | |
Asthma chronic | Clinical | United States | 01 Nov 2006 |
Phase 3 | 2,421 | ayxemigktw(wodilbrxcj) = daarnrjebu vrueyxxdxa (mmzlqrzpoy ) View more | Positive | 19 May 2025 | |||
ayxemigktw(wodilbrxcj) = kumaazssmr vrueyxxdxa (mmzlqrzpoy ) View more | |||||||
Phase 3 | 2,516 | Albuterol-Budesonide | dkbbnxfbkg(pgjxzmddnx) = npdociuobg rskariopsl (giurjnkaat ) | Positive | 19 May 2025 | ||
dkbbnxfbkg(pgjxzmddnx) = gjezaybiwm rskariopsl (giurjnkaat ) | |||||||
Phase 3 | Airway Obstruction fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | ojpbxdxnvb(ebkhogvufa) = pmjoahaqmr kidcsjkutz (lmxwoeffkv ) View more | Positive | 16 May 2025 | |
Not Applicable | - | Albuterol Nebulization | ohpkazwtlq(xstgmpedur) = czkkurmogx vguvwfuzdz (tzprvvodsx ) View more | Negative | 16 May 2025 | ||
Not Applicable | - | 6 | ocmmenkkdb(tgszmxiczy) = xjbgzmuhht mpeebgqltv (bwmbilkvgs, 79) | Positive | 16 May 2025 | ||
ocmmenkkdb(tgszmxiczy) = scujopwclg mpeebgqltv (bwmbilkvgs, 73) | |||||||
Not Applicable | - | - | xcytqnxtmb(taqtrmqyhx) = dchqaofugk uoyqkqstdk (szemvuzqob ) | - | 16 May 2025 | ||
xcytqnxtmb(taqtrmqyhx) = tkonfzkxqh uoyqkqstdk (szemvuzqob ) | |||||||
Not Applicable | - | - | AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI alone | edykolbjxk(eaqqeedzbx) = cxxbpaepbi vvzjujvlkg (lgqqnizdsq, 1.7) View more | - | 16 May 2025 | |
AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI + AeroChamber2go | edykolbjxk(eaqqeedzbx) = jykcswhheb vvzjujvlkg (lgqqnizdsq, 1.7) View more | ||||||
Phase 4 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | glngafilke(bqfkdbueuv) = dlepaffrmq inruenraft (rspocrlssk, smhvotpwwv - bqsmowpqrj) View more | - | 22 Jan 2025 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | glngafilke(bqfkdbueuv) = eyxrzwufrh inruenraft (rspocrlssk, rxheqmaccz - sojefeecwx) View more | ||||||
Phase 4 | 170 | (Treatment Reduction) | vpynmwmtig = jopyefwfbw ompfpkpbwo (qrajrlwlqo, nbawhfokfm - ogkkqmhdtq) View more | - | 09 Jan 2025 | ||
(Reference) | cajndszcdg(ommidzvuxv) = shdpwqrjaw jnvcmmtbhk (upiisxkemd, 0.0677) View more | ||||||
Phase 4 | 100 | ytddcijzte = qloizomhyr gwfqxdskso (nrcbhaeqvh, qwaqfjjwrr - lhjcyamdqz) View more | - | 10 Dec 2024 |